DNM1L and gallbladder cancer: These findings suggest that the USP3–DNM1L axis drives the malignant phenotype of gallbladder cancer via the “mitochondrial dynamics-metabolic reprogramming-tumor progression” pathway, providing a theoretical basis for therapeutic strategies targeting mitochondrial metabolism.